NMS·Healthcare·$756M·#508 / 520 in Healthcare
ACRS Aclaris Therapeutics, Inc.
15CRITICAL
CATEGORY BREAKDOWN
GROWTH0
QUALITY6
STABILITY39
VALUATION0
GOVERNANCE13
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-58.2%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
6.9%
9
> 50% strong
Cash Runway
Months of cash at current burn rate
5 months
8
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
0.4%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
90.4x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-1005
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
2.3%
18
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+28.9%
1
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ACRS WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when ACRS's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.